Posted by Michael Wonder on 23 Mar 2021
Zealand Pharma announces FDA approval of Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycaemia in people with diabetes
22 March 2021 - Approval based on results from three pivotal trials in adults and children with diabetes, showing median time to blood glucose recovery from severe hypoglycaemia of 10 minutes following injection of 0.6 mg/0.6 mL Zegalogue.
Zealand Pharma announced today that the U.S. FDA has approved Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes aged 6 years and above.
